15.31
+6.84%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Trevi Therapeutics
From its filings with the US Securities and Exchange Commission
Trevi Therapeutics is based in New Haven, Connecticut and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TRVI. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $42.8m. At that date it held total assets of $193.4m and shareholders' equity of $183.2m.
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC.
Haduvio is an oral extended-release formulation of nalbuphine. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa receptor agonist and a mu receptor antagonist (“KAMA”), targeting opioid receptors that play a key role in controlling chronic cough. The kappa- and mu-opioid receptors are known to be critical mediators of cough. Nalbuphine has been approved and marketed as an injectable for pain indications for decades in the United States, or the U.S., and Europe. Nalbuphine’s mechanism of action also mitigates the risk of abuse associated with mu-opioid agonists because it antagonizes, or blocks, the mu-opioid receptor. Parenteral nalbuphine is not scheduled as a controlled substance by the U.S. Drug Enforcement Agency and in most of Europe. We believe this makes Haduvio a promising potential therapy for the treatment of chronic cough in patients with IPF, non-IPF ILD, and RCC.
Quoted from its 10-K, filed 17 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 May 2019
- Employees
- 34
- Website
- trevitherapeutics.com ↗
- Head office
- 195 CHURCH STREET, NEW HAVEN, CT, 06510
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. David MeekerIndependent Chairman of the Board$143,246
- Ms. Jennifer GoodPresident, Chief Executive Officer, Director, since 2011$2.6m
- Dr. Thomas SciasciaCo-Founder, Chief Scientific Officer$977,125
- Mr. David HastingsChief Financial Officer
- Dr. James CassellaChief Development Officer, since 2020$1.5m
- Dr. Farrell SimonChief Commercial Officer
- Mr. Dominick ColangeloIndependent Director$125,746
- Mr. Michael HeffernanIndependent Director$133,246
- Mr. Edward MathersIndependent Director$115,746
- Ms. Anne VanlentIndependent Director$133,246
- Mr. Jonathan CarlsonIR Contact Officer, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 35
- Environment
- 37
- Social
- 43
- Governance
- 25
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Trevi Therapeutics focuses on clinical-stage biopharmaceutical development with Haduvio for chronic cough and prurigo nodularis treatment.
- Haduvio is an oral extended-release formulation of nalbuphine targeting neurologically mediated conditions.
- Trevi Therapeutics conducts Phase IIb/III trials for pruritus and Phase II CANAL trials for chronic cough in IPF patients.
Weaknesses
- Trevi Therapeutics has only 34 employees, which may limit operational capacity.
- The company's IPO in 2019 may indicate limited financial resources for expansion.
- Trevi Therapeutics is a clinical-stage company with no commercialized products yet.
Opportunities
- Haduvio's potential approval could address unmet needs in chronic cough and prurigo nodularis markets.
- The Phase II CANAL trial for IPF-related chronic cough presents a significant market opportunity.
- Trevi Therapeutics can expand its development programs for additional neurologically mediated conditions.
Threats
- Competition from other pharmaceutical companies in the chronic cough and pruritus treatment sectors.
- Regulatory delays in approving Haduvio for chronic cough and prurigo nodularis indications.
- The failure of Phase IIb/III trials could halt development of Haduvio.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.